Core Viewpoint - Changjiang Life Sciences Technology (00775) has established a Scientific Advisory Committee to support its research projects, particularly in therapeutic cancer vaccines, amidst a complex global drug development environment [1][5]. Group 1: Company Developments - Changjiang Life Sciences Technology's stock price increased by 3.57% to HKD 0.87, with a trading volume of HKD 35.51 million [1][5]. - The newly formed Scientific Advisory Committee consists of independent experts from academia, clinical research, and industry, including notable figures such as former Secretary for Food and Health Ko Wing-man and clinical professor at HKU, Dr. Hsu Yi-wen [1][5]. Group 2: Strategic Initiatives - The committee is a strategic organization that will provide scientific, clinical, and regulatory guidance to accelerate the company's research projects, including several therapeutic cancer vaccines that are preparing for clinical trials [1][5]. - The Scientific Advisory Committee will also offer professional resources to help the company navigate the increasingly complex global drug development landscape, mitigate risks, and expedite regulatory approvals and patient access [1][5].
长江生命科技现涨近4% 公司成立科学顾问委员会推进科研项目全速前进